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  43 
Summary 44 
Individuals with severe, undiagnosed developmental disorders (DDs) are enriched for damaging 45 
de novo mutations (DNMs) in developmentally important genes. We exome sequenced 4,293 46 
families with individuals with DDs, and meta-analysed these data with another 3,287 individuals 47 
with similar disorders. We show that the most significant factors influencing the diagnostic yield 48 
of DNMs are the sex of the affected individual, the relatedness of their parents, whether close 49 
relatives are affected and parental ages. We identified 94 genes enriched for damaging DNMs, 50 
including 14 without previous compelling evidence. We have characterised the phenotypic 51 
diversity among these disorders. We estimate that 42% of our cohort carry pathogenic DNMs in 52 
coding sequences, and approximately half disrupt gene function, with the remainder resulting 53 
in altered-function. We estimate that developmental disorders caused by DNMs have an 54 
average birth prevalence of 1 in 213 to 1 in 448, depending on parental age. Given current 55 
global demographics, this equates to almost 400,000 children born per year. 56 
Main text 57 
Approximately 2-5% of children are born with major congenital malformations and/or manifest 58 
severe neurodevelopmental disorders during childhood1,2. While diverse mechanisms can cause 59 
such developmental disorders, including gestational infection and maternal alcohol 60 
consumption, damaging genetic variation in developmentally important genes has a major 61 
contribution. Several recent studies have identified a substantial causal role for DNMs not 62 
present in either parent3-16. Despite the identification of many developmental disorders caused 63 
by DNMs, it is generally accepted that many more such disorders await discovery15, and the 64 
overall contribution of DNMs to developmental disorders is not known. Moreover, some 65 
pathogenic DNMs completely ablate the function of the encoded protein, whereas others alter 66 
the function of the encoded protein17; the relative contributions of these two mechanistic 67 
classes is also not known. 68 
 69 
We recruited 4,293 individuals to the Deciphering Developmental Disorders (DDD) study15 via 70 
genetics services of the UK National Health Service and Republic of Ireland. Each of these 71 
individuals was referred with a severe undiagnosed developmental disorder and most were the 72 
only affected family member. Most (81%) individuals had been screened for large pathogenic 73 
deletions and duplications. We systematically phenotyped these individuals and sequenced the 74 
exomes of these individuals and their parents. Growth measurements, family history, and 75 
developmental milestones were collected, and detailed clinical phenotypes were captured 76 
using Human Phenotype Ontology (HPO) terms. Analyses of 1,133 of these trios were described 77 
previously15,18. We generated a high sensitivity set of 8,361 candidate DNMs in coding or 78 
splicing sequence (mean of 1.95 DNMs per proband), while removing systematic erroneous 79 
calls (Supplementary Table 1). This rate of candidate DNMs per proband is higher than other 80 
studies3-15, because we wish to maintain high sensitivity, and can address lower specificity via 81 
subsequent validation. 1,624 genes contained two or more DNMs in unrelated individuals. 82 
 83 
Twenty-three percent of individuals had likely pathogenic protein-truncating or missense DNMs 84 
within the clinically curated set of genes robustly associated with dominant developmental 85 
disorders18. We investigated factors associated with whether an individual had a likely 86 
pathogenic DNM in these curated genes (Figure 1a, b, Supplementary Table 1). We observed 87 
that males had a lower chance of carrying a likely pathogenic DNM (P = 1.6 x 10-4; OR 0.75, 0.65 88 
- 0.87 95% CI), as has also been observed in autism19. We also observed increased likelihood of 89 
having a pathogenic DNM with the extent of speech delay (P = 0.00115), but not other 90 
indicators of severity relative to the rest of the cohort. Individuals with other affected family 91 
members were less likely to have pathogenic DNMs (affected siblings: P = 7.3 x 10-18, affected 92 
parents: P = 5.7 x 10-9), and individuals who were from self-declared consanguineous unions 93 
were less likely to have a pathogenic DNM (P = 8.0 x 10-11). Furthermore, the total genomic 94 
extent of autozygosity (due to parental relatedness) was negatively correlated with the 95 
likelihood of having a pathogenic DNM (P = 1.7 x 10-7), for every log10 increase in autozygous 96 
length, the probability of having a pathogenic DNM dropped by 7.5%, likely due to increasing 97 
burden of recessive causation (Figure 1c). Nonetheless, 6% of individuals with autozygosity 98 
equivalent to a first cousin union or greater had a plausibly pathogenic DNM, underscoring the 99 
importance of considering de novo causation in all families.  100 
 101 
Paternal age has been shown to be the primary factor influencing the number of DNMs in a 102 
child20,21, and thus is expected to be a risk factor for pathogenic DNMs. Paternal age was only 103 
weakly associated with likelihood of having a pathogenic DNM (P = 0.016). However, focusing 104 
on the minority of DNMs that were truncating and missense variants in known DD-associated 105 
genes limits our power to detect such an effect. Analysing all 8,409 high confidence exonic and 106 
intronic autosomal DNMs confirmed a strong paternal age effect (P = 1.4 x 10-10, 1.53 107 
DNMs/year, 1.07-2.01 95% CI), as well as highlighting a weaker, independent, maternal age 108 
effect (P = 0.0019, 0.86 DNMs/year, 0.32-1.40 95% CI, Figure 1d,e), as has recently been 109 
described in whole genome analyses22. These genome-wide estimates were scaled from exome-110 
based estimates, of 0.0306 DNMs/year paternal effect and 0.0172 DNMs/year maternal effect. 111 
 112 
We identified genes significantly enriched for damaging DNMs by comparing the observed 113 
gene-wise DNM count to that expected under a null mutation model23, as described 114 
previously15. We combined this analysis with 4,224 published DNMs in 3,287 affected 115 
individuals from thirteen exome or genome sequencing studies (Supplementary Table 2)3-14 that 116 
exhibited a similar excess of DNMs in our curated set of DD-associated genes (Extended Data 117 
Figure 1). We found 93 genes with genome-wide significance (P < 5 × 10-7, Figure 2), 80 of which 118 
had prior evidence of DD-association (Supplementary Table 3). We have developed visual 119 
summaries of the phenotypes associated with each gene to facilitate clinical use. In addition, 120 
we created anonymised average face images from individuals with DNMs in genome-wide 121 
significant genes (Figure 2) from ordinary (2D) clinical photos using previously validated 122 
software24. These images highlight facial dysmorphologies specific to certain genes. After 123 
careful review by two experienced clinical geneticists, average face images for twelve genes 124 
were determined to be truly anonymised and of sufficient quality.To assess any increase in 125 
power to detect novel DD-associated genes, we excluded individuals with likely pathogenic 126 
variants in known DD-associated genes15, leaving 3,158 probands from our cohort, along with 127 
2,955 probands from the meta-analysis studies. In this subset, fourteen genes for which no 128 
statistically-compelling prior evidence for DD causation was available achieved genome-wide 129 
significance: CDK13, CHD4, CNOT3, CSNK2A1, GNAI1, KCNQ3, MSL3, PPM1D, PUF60, QRICH1, 130 
SET, SUV420H1, TCF20, and ZBTB18 (P < 5 x 10-7, Table 1, Extended Data Figure 4). The clinical 131 
features associated with these newly confirmed disorders are summarised in Extended Data 132 
Figure 2, Extended Data Figure 3 and Supplementary Information. QRICH1 would not achieve 133 
genome-wide significance without excluding individuals with likely pathogenic variants in DD-134 
associated genes. In addition to discovering novel DD-associated genes, we identified several 135 
new disorders linked to known DD-associated genes, but with different modes of inheritance or 136 
molecular mechanisms. We found USP9X and ZC4H2 had a genome-wide significant excess of 137 
DNMs in female probands, indicating these genes have X-linked dominant modes of inheritance 138 
in addition to previously reported X-linked recessive mode of inheritance in males25,26. In 139 
addition, we found truncating mutations in SMC1A were strongly associated with a novel 140 
seizure disorder (P = 6.5 x 10-19), while in-frame/missense mutations in SMC1A with dominant 141 
negative effects27 are a known cause of Cornelia de Lange Syndrome (CdLS). Individuals with 142 
truncating mutations in SMC1A lacked the characteristic facial dysmorphology of CdLS. 143 
 144 
We then explored two approaches for integrating phenotypic data into disease gene 145 
association: statistical assessment of Human Phenotype Ontology (HPO) term similarity 146 
between individuals sharing candidate DNMs in the same gene (as we described previously28) 147 
and phenotypic stratification based on specific clinical characteristics. Combining genetic 148 
evidence and HPO term similarity increased the significance of some known DD-associated 149 
genes.  However, significance decreased for a larger number of genes causing severe DD but 150 
associated with non discriminative HPO terms (Extended Data Figure 5a). Although we did not 151 
incorporate categorical phenotypic similarity in the gene discovery analyses described above, 152 
the systematic acquisition of phenotypic data on affected individuals within DDD enabled 153 
aggregate representations to be created for each gene achieving genome-wide significance. We 154 
present these in the form of icon-based summaries of growth and developmental milestones 155 
(PhenIcons), heatmaps of the recurrently coded HPO terms and, where photos for at least ten 156 
children with mutations in the same gene were available, an anonymised average facial 157 
representation (Supplementary Information).   158 
 159 
Twenty percent of individuals had HPO terms which indicated seizures and/or epilepsy.  We 160 
compared analysis within this phenotypically stratified group with gene-wise analyses of the 161 
entire cohort, to see if it increased power to detect known seizure-associated genes (Extended 162 
Data Figure 5b). Fifteen seizure-associated genes were genome-wide significant in both the 163 
seizure-only and the entire-cohort analyses. Nine seizure-associated genes were genome-wide 164 
significant in the entire cohort but not in the seizure subset. Of the 285 individuals with 165 
truncating or missense DNMs in known seizure-associated genes, 56% of individuals had no 166 
coded terms related to seizures/epilepsy. These findings suggest that the power of increased 167 
sample size far outweighs specific phenotypic expressivity due to the shared genetic etiology 168 
between individuals with and without epilepsy in our cohort. Despite this, nearly three times as 169 
many individuals with seizures had a DNM in a seizure-associated gene compared to individuals 170 
without seizures (Extended Data Figure 5c). At matched sample sizes, more genes exceeded 171 
genomewide significance in seizure samples than in unstratified samples (Extended Data Figure 172 
5d). This highlights the cost-benefit of recruiting a phenotypically more homogenous cohort. 173 
 174 
The large number of genome-wide significant genes identified in the analyses above allows us 175 
to compare empirically different experimental strategies for novel gene discovery in a 176 
genetically heterogeneous cohort. We compared the power of exome and genome sequencing 177 
to detect genome-wide significant genes, assuming that budget and not samples are limiting, 178 
under different scenarios of cost ratios and sensitivity ratios (Extended Data Figure 6a). At 179 
current cost ratios (exome costs 30-40% of a genome) and with a plausible sensitivity 180 
differential (genome detects 5% more exonic variants than exome29) exome sequencing detects 181 
more than twice as many genome-wide significant genes. These empirical estimates were 182 
consistent with power simulations for identifying dominant loss-of-function genes (Extended 183 
Data Figure 6b). In summary, while genome sequencing gives greatest sensitivity to detect 184 
pathogenic variation in a single individual (or outside of the coding region), exome sequencing 185 
is more powerful for novel disease gene discovery (and, analogously, likely delivers lower cost 186 
per diagnosis currently). 187 
 188 
Our previous simulations suggested that analysis of a cohort of 4,293 DDD families ought to be 189 
able to detect approximately half of all haploinsufficient DD-associated genes at genome-wide 190 
significance15. Empirically, we have identified 47% (50/107) of haploinsufficient genes 191 
previously robustly associated with neurodevelopmental disorders18. We hypothesised that 192 
genetic testing prior to recruitment into our study may have depleted the cohort of the most 193 
clinically recognisable disorders. Indeed, we observed that the genes associated with the most 194 
clinically recognisable disorders were associated with a significant, three-fold lower enrichment 195 
of truncating DNMs than other DD-associated genes (~40-fold enrichment vs ~120-fold 196 
enrichment, Figure 3a). Removing these most recognisable disorders from the analysis, we 197 
identified 55% (42/76) of the remaining haploinsufficient DD-associated genes. The known DD-198 
associated haploinsufficient genes that did not reach genome-wide significance were clearly 199 
enriched for those with lower mutability, which we would expect to lower power to detect in 200 
our analyses. We identified DD-associated genes (e.g. NRXN2) with high mutability, low clinical 201 
recognisability and yet no signal of enrichment for DNMs in our cohort, as assessed by ΔAIC 202 
(Extended Data Figure 7, Supplementary Table 4). Our analyses call into question whether these 203 
genes really are associated with haploinsufficient neurodevelopmental disorders and highlights 204 
the potential for well-powered gene discovery analyses to refute prior credence regarding 205 
disease gene associations or prior inferences regarding an underlying haploinsufficient 206 
mechanism.  207 
 208 
We estimated the likely prevalence of pathogenic missense and truncating DNMs within our 209 
cohort by increasing the stringency of called DNMs until the observed synonymous DNMs 210 
equated that expected under the null mutation model (Extended Data Figure 8a), then 211 
quantifying the excess of observed missense and truncating DNMs across all genes (Figure 3b). 212 
We observed an excess of 576 truncating and 1,220 missense mutations, suggesting 41.8% 213 
(1,796/4,293) of the cohort has a pathogenic DNM. This estimate of the number of excess 214 
missense and truncating DNMs in our cohort is robust to varying the stringency of DNM calling 215 
(Extended Data Figure 8b). The vast majority of synonymous DNMs are likely to be benign, as 216 
evidenced by them being distributed uniformly (Figure 3d) among genes irrespective of their 217 
tolerance of truncating variation in the general population (as quantified by the probability of 218 
being LoF-intolerant (pLI) metric30). By contrast, missense and truncating DNMs are significantly 219 
enriched in genes with the highest probabilities of being intolerant of truncating variation 220 
(Figure 3d). The pLI-based distributions were similar to distributions which used functional 221 
constraint (Extended Data Figure 9)31. Only 51% (923/1,796) of these excess missense and 222 
truncating DNMs are located in DD-associated dominant genes, with the remainder likely to 223 
affect genes not yet associated with DDs. A much higher proportion of the excess truncating 224 
DNMs (71%) than missense DNMs (42%) affected known DD-associated genes. This suggests 225 
that whereas most haploinsufficient DD-associated genes have already been identified, many 226 
DD-associated genes characterised by pathogenic missense DNMs remain to be discovered. 227 
 228 
Understanding the mechanism of action of a monogenic disorder is an important prerequisite 229 
for designing therapeutic strategies32. We sought to estimate the relative proportion of altered-230 
function and loss-of-function mechanisms among the excess DNMs in our cohort, by assuming 231 
that the vast majority of truncating mutations operate by a loss-of-function mechanism and 232 
using two independent approaches to estimate the relative contribution of the two 233 
mechanisms among the excess missense DNMs (Methods). First, we used the observed ratio of 234 
truncating and missense DNMs within haploinsufficient DD-associated genes to estimate the 235 
proportion of the excess missense DNMs that likely act by loss-of-function (Figure 3c). This 236 
approach estimated that 59% (55 - 64% 95% CI) of excess missense and truncating DNMs 237 
operate by loss-of-function, and 41% by altered-function. Second, we took advantage of the 238 
different population genetic characteristics of known altered-function and loss-of-function DD-239 
associated genes. Specifically, we observed that these two classes of DD-associated genes are 240 
differentially depleted of truncating variation in individuals without overt developmental 241 
disorders (pLI metric30). We modelled the observed pLI distribution of excess missense DNMs as 242 
a mixture of the pLI distributions of known altered-function and loss-of-function DD-associated 243 
genes (Figure 3e, f), and estimated that 63% (50 - 76% 95% CI) of excess missense DNMs likely 244 
act by altered-function mechanisms. Incorporating the truncating DNMs operating by a loss-of-245 
function mechanism, this approach estimated that 57% (48 - 66% 95% CI) of excess missense 246 
and truncating DNMs operate by loss-of-function and 43% by altered-function. 247 
 248 
We estimated the birth prevalence of monoallelic developmental disorders by using the 249 
germline mutation model to calculate the expected cumulative germline mutation rate of 250 
truncating DNMs in haploinsufficient DD-associated genes and scaling this upwards based on 251 
the composition of excess DNMs in the DDD cohort described above (see Methods), correcting 252 
for disorders that are under-represented in our cohort as a result of prior genetic testing (e.g. 253 
clinically-recognisable disorders and large pathogenic CNVs identified by prior chromosomal 254 
microarray analysis). This gives a mean prevalence estimate of 0.34% (0.31-0.37 95% CI), or 1 in 255 
295 births. By factoring in the paternal and maternal age effects on the mutation rate (Figure 1) 256 
we modelled age-specific estimates of birth prevalence (Figure 4) that range from 1 in 448 257 
(both mother and father aged 20) to 1 in 213 (both mother and father aged 45). Assuming a 258 
yearly global birth rate of 18.6 live births/1000 individuals, and a mean age when giving birth of 259 
26.6 years, nearly 400,000 of the 140 million annual births will have a developmental disorder 260 
caused by a DNM. 261 
 262 
In summary, we have shown that de novo mutations account for approximately half of the 263 
genetic architecture of severe developmental disorders, and are split roughly equally between 264 
loss-of-function and altered-function. Whereas most haploinsufficient DD-associated genes 265 
have already been identified, currently many activating and dominant negative DD-associated 266 
genes have eluded discovery. This elusiveness likely results from these disorders being 267 
individually rarer, being caused by a relatively small number of missense mutations within each 268 
gene. It would be valuable to estimate the penetrance of de novo mutations in the genes we 269 
identified exceeding genome-wide significance, but we cannot formally assess penetrance with 270 
our data. Future evaluations could integrate depletion of damaging variation in large healthy 271 
populations with patterns of segregation in affected families. Discovery of the remaining 272 
dominant developmental disorders requires larger studies and novel, more powerful, analytical 273 
strategies for disease-gene association that leverage gene-specific patterns of population 274 
variation, specifically the observed depletion of damaging variation. The integration of accurate 275 
and complete quantitative and categorical phenotypic data into the analysis will improve the 276 
power to identify ultrarare DD with distinctive clinical presentations. We have estimated the 277 
mean birth prevalence of dominant monogenic developmental disorders to be around 1 in 295, 278 
which is greater than the combined impact of trisomies 13, 18 and 2133 and highlights the 279 
cumulative population morbidity and mortality imposed by these individually rare disorders. 280 
 281 
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Tables 459 
Table 1: Genes achieving genome-wide significant statistical evidence without previous compelling 460 
evidence for being developmental disorder genes. The numbers of unrelated individuals with 461 
independent de novo mutations (DNMs) are given for protein truncating variants (PTV) and missense 462 
variants. Counts of individuals in other cohorts are given in brackets if present. The P-value reported is 463 
the minimum P-value from the testing of the DDD dataset or the meta-analysis dataset. The subset 464 
providing the P-value is also listed. Mutations are considered clustered if the P-value from proximity 465 
clustering of DNMs is less than 0.01. 466 
Gene Missense PTV P-value Test Clustering 
CDK13 10 1 3.2 x 10-19 DDD Yes 
GNAI1 7 (1) 1 2.1 x 10-13 DDD No 
CSNK2A1 7 0 1.4 x 10-12 DDD Yes 
PPM1D 0 5 (1) 6.3 x 10-12 Meta No 
CNOT3 5 2 (1) 5.2 x 10-11 DDD Yes 
MSL3 0 4 2.2 x 10-10 DDD No 
KCNQ3 4 (3) 0 3.4 x 10-10 Meta Yes 
ZBTB18 1 (1) 4 1.4 x 10-9 DDD No 
PUF60 4 (1) 3 2.6 x 10-9 DDD No 
TCF20 1 5 2.7 x 10-9 DDD No 
SUV420H1 0 (2) 2 (3) 2.9 x 10-9 Meta No 
CHD4 8 (1) 1 7.6 x 10-9 DDD No 
SET 0 3 1.2 x 10-7 DDD No 
QRICH1 0 3 (1) 3.6 x 10-7 Meta No 
 467 
  468 
Extended data tables 469 
 470 
Extended Data Table 1: Phenotypes tested for association with having a pathogenic de novo mutation. 471 
 472 
Category Phenotype Type Value 95% CI P-value 
Post-natal 
abnormal cranial MRI Odds ratio 1.365 1.125 – 1.656 0.002 
feeding problems Odds ratio 1.176 1.01 – 1.369 0.039 
neonatal intensive care Odds ratio 0.896 0.762 – 1.054 0.190 
anticonvulsant drugs Odds ratio 0.582 0.246 – 1.377 0.270 
Pre-natal 
bleeding Odds ratio 0.892 0.714 – 1.114 0.346 
maternal illness Odds ratio 0.908 0.764 – 1.079 0.278 
maternal diabetes Odds ratio 0.787 0.504 – 1.229 0.341 
abnormal scan Odds ratio 0.839 0.692 – 1.017 0.078 
assisted reproduction Odds ratio 0.868 0.554 – 1.36 0.584 
increased nuchal 
translucency 
Odds ratio 1.432 0.903 – 2.271 0.126 
Family history 
consanguinity Odds ratio 0.234 0.138 – 0.397 8.0 x 10-11 
similar phenotype parents Odds ratio 0.295 0.184 – 0.474 5.7 x 10-9 
similar phenotype relatives Odds ratio 0.553 0.402 – 0.761 1.5 x 10-4 
similar phenotype siblings Odds ratio 0.311 0.23 – 0.421 7.3 x 10-18 
only patient affected Odds ratio 2.478 2.001 – 3.068 3.9 x 10-19 
X-linked inheritance Odds ratio 0.839 0.436 – 1.613 0.752 
Multiple births Beta 0.043 -0.058 – 0.144 0.403 
History of pregnancy loss Beta -0.039 -0.155 – 0.078 0.516 
Developmental 
milestones 
first words Beta 0.205 0.081 – 0.328 0.001 
walked independently Beta 0.125 0.016 – 0.235 0.025 
sat independently Beta 0.050 -0.069 – 0.17 0.408 
social smile Beta 0.072 -0.066 – 0.211 0.305 
Growth 
height Beta 0.008 -0.111 – 0.126 0.897 
birthweight Beta -0.018 -0.135 – 0.098 0.756 
OFC Beta -0.094 -0.215 – 0.026 0.125 
weight Beta -0.331 -1.278 – 0.615 0.493 
Age 
age at assessment Beta 0.116 0.015 – 0.217 0.025 
gestation Beta 0.079 -0.033 – 0.19 0.167 
father's age Beta 0.137 0.027 – 0.247 0.015 
mother's age  Beta 0.108 -0.003 – 0.219 0.056 
Other 
phenotypic terms (n) Beta 0.104 0.004 – 0.203 0.041 
autozygosity length Beta -0.185 -0.254 – -0.115 1.6 x 10-7 
sex (male) Odds ratio 0.750 0.646 – 0.87 1.6 x 10-4 
Supplementary Table Legends 473 
Note: These are included in the supplementary info, but are required here for the auto-474 
numbering. 475 
 476 
Supplementary Table 1: Table of de novo mutations (DNM) in the 4,293 DDD individuals. The table 477 
includes sex, chromosome, position, reference and alternate alleles, HGNC symbol, VEP consequence, 478 
posterior probability of DNM and validation status where available. Individual IDs are available on 479 
request. This list excludes the sites that failed validations, but includes sites that passed validation 480 
(confirmed), sites that were uncertain (uncertain), and sites that were not tested by secondary 481 
validation (NA). Genome positions are given as GRCh37 coordinates. 482 
Supplementary Table 2: Details of cohorts used in meta-analyses. This includes numbers of individuals 483 
by sex and publication details. 484 
Supplementary Table 3: Genes with genome-wide significant statistical evidence to be developmental 485 
disorder genes. The numbers of unrelated individuals with independent de novo mutations (DNMs) are 486 
given for protein truncating variants (PTV) and missense variants. If any additional individuals were in 487 
other cohorts, that number is given in brackets. The P-value reported is the minimum P-value from the 488 
testing of the DDD dataset or the meta-analysis dataset. The subset providing the P-value is also listed. 489 
Mutations are considered clustered if the P-value proximity clustering of DNMs is less than 0.01. 490 
Supplementary Table 4: Comparison of known haploinsufficient (HI) neurodevelopment genes to HI and 491 
non-HI enrichment models. Genes are ranked by difference in the Akaike’s Information Criterion 492 
computed for models where the genes match either expected non-HI PTV enrichment (model 1), or 493 
expected HI protein-truncating variant (PTV) enrichment (model 2). 494 




Figure 1: Association of phenotypes with presence of likely pathogenic de novo mutations (DNMs). a, 499 
Odds ratios for binary phenotypes. Positive odds ratios are associated with increased risk of pathogenic 500 
DNMs when the phenotype is present. P-values are given for a Fisher’s Exact test. b, Beta coefficients 501 
from logistic regression of quantitative phenotypes versus presence of a pathogenic DNM. All 502 
phenotypes aside from length of autozygous regions were corrected for gender as a covariate. The 503 
developmental milestones (age to achieve first words, walk independently, sit independently and social 504 
smile) were log-scaled before regression. The growth parameters (height, birthweight and 505 
occipitofrontal circumference (OFC)) were evaluated as absolute distance from the median. c, 506 
Relationship between length of autozygous regions chance of having a pathogenic DNM. The regression 507 
line is plotted as the dark gray line. The 95% confidence interval for the regression is shaded gray. The 508 
autozygosity lengths expected under different degrees of consanguineous unions are shown as vertical 509 
dashed lines. n, number of individuals in each autozygosity group. d, Relationship between age of 510 
fathers at birth of child and number of high confidence DNMs. n, number of high confidence DNMs. e, 511 
Relationship between age of mothers at birth of child and number of high confidence DNMs. Error bars 512 
indicate 95% c.i. n, number of high confidence DNMs.  513 
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bleeding P = 0.346
maternal illness P = 0.278
abnormal scan P = 0.0784
assisted reproduction P = 0.584
affected sibling P = 7.3 x 10-18
affected parent P = 5.7 x 10-9
affected relative P = 1.5x10-4
consanguinity P = 8.0 x 10-11
only affected member P = 3.9 x10-19
 515 
Figure 2: Genes exceeding genome-wide significance. Manhattan plot of combined P-values across all 516 
tested genes. The red dashed line indicates the threshold for genome-wide significance (P < 7 x 10-7). 517 
Genes exceeding this threshold have HGNC symbols labelled. De-identified realistic average 518 
(‘composite’) faces were generated using previously validated software24 from clinical photos from 519 
individuals with DNMs in the same gene, and are shown here for the six most-significantly associated 520 
genes. Confirmation of de-identification was performed by careful review by two experienced clinical 521 
geneticists. Each face was generated from clinical photos of more than ten children.  522 
  523 
 524 
Figure 3: Excess of de novo mutations (DNMs). a, Enrichment ratios of observed to expected loss-of-525 
function DNMs by clinical recognisability for dominant haploinsufficient neurodevelopmental genes as 526 
judged by two consultant clinical geneticists. Error bars indiciate 95% CI. b, Enrichment of DNMs by 527 
consequence normalised relative to the number of synonymous DNMs. c, Proportion of excess DNMs 528 
with loss-of-function or altered-function mechanisms. Proportions are derived from numbers of excess 529 
DNMs by consequence, and numbers of excess truncating and missense DNMs in dominant 530 
haploinsufficient genes. d, Enrichment ratios of observed to expected DNMs by pLI constraint quantile 531 
for loss-of-function, missense and synonymous DNMs. Counts of DNMs in each lower and upper half of 532 
the quantiles are provided. e, Normalised excess of observed to expected DNMs by pLI constraint 533 
quantile. This includes missense DNMs within all genes, loss-of-function including missense DNMs in 534 
dominant haploinsufficient genes and missense DNMs in dominant nonhaploinsufficient genes (genes 535 
with dominant negative or activating mechanisms). f, Proportion of excess missense DNMs with a loss-536 
of-function mechanism. The red dashed line indicates the proportion in observed excess DNMs at the 537 
optimal goodness-of-fit. The histogram shows the frequencies of estimated proportions from 1000 538 
permutations, assuming the observed proportion is correct.  539 
  540 
 541 
Figure 4: Prevalence of live births with developmental disorders caused by dominant de novo mutations 542 
(DNMs). The prevalence within the general population is provided as percentage for combinations of 543 
parental ages, extrapolated from the maternal and paternal rates of DNMs. Distributions of parental 544 
ages within the DDD cohort and the UK population are shown at the matching parental axis. 545 
 546 






























0.24 0.26 0.28 0.29 0.31 0.33 0.35 0.37 0.39
0.25 0.27 0.29 0.31 0.32 0.34 0.36 0.38 0.40
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0.30 0.32 0.34 0.36 0.38 0.40 0.42 0.43 0.45
0.31 0.33 0.35 0.37 0.39 0.41 0.43 0.45 0.46

























Family recruitment 549 
At 24 clinical genetics centers within the United Kingdom (UK) National Health Service and the 550 
Republic of Ireland, 4,293 patients with severe, undiagnosed developmental disorders and their 551 
parents (4,125 families) were recruited and systematically phenotyped. The study has UK 552 
Research Ethics Committee approval (10/H0305/83, granted by the Cambridge South Research 553 
Ethics Committee and GEN/284/12, granted by the Republic of Ireland Research Ethics 554 
Committee). Families gave informed consent for participation. 555 
 556 
Clinical data (growth measurements, family history, developmental milestones, etc.) were 557 
collected using a standard restricted-term questionnaire within DECIPHER34, and detailed 558 
developmental phenotypes for the individuals were entered using Human Phenotype Ontology 559 
(HPO) terms35. Saliva samples for the whole family and blood-extracted DNA samples for the 560 
probands were collected, processed and quality controlled as previously described15. 561 
 562 
Exome sequencing  563 
Genomic DNA (approximately 1 μg) was fragmented to an average size of 150 base-pairs (bp) 564 
and subjected to DNA library creation using established Illumina paired-end protocols. Adaptor-565 
ligated libraries were amplified and indexed via polymerase chain reaction (PCR). A portion of 566 
each library was used to create an equimolar pool comprising eight indexed libraries. Each pool 567 
was hybridized to SureSelect ribonucleic acid (RNA) baits (Agilent Human All-Exon V3 Plus with 568 
custom ELID C0338371 and Agilent Human All-Exon V5 Plus with custom ELID C0338371) and 569 
sequence targets were captured and amplified in accordance with the manufacturer's 570 
recommendations. Enriched libraries were subjected to 75-base paired-end sequencing 571 
(Illumina HiSeq) following the manufacturer's instructions. 572 
 573 
Alignment and calling single nucleotide variants, insertions and deletions 574 
Mapping of short-read sequences for each sequencing lanelet was carried out using the 575 
Burrows-Wheeler Aligner (BWA; version 0.59)36 backtrack algorithm with the GRCh37 1000 576 
Genomes Project phase 2 reference (also known as hs37d5). Sample-level BAM improvement 577 
was carried out using the Genome Analysis Toolkit (GATK; version 3.1.1)37 and SAMtools 578 
(version 0.1.19)38. This consisted of a realignment of reads around known and discovered indels 579 
followed by base quality score recalibration (BQSR), with both steps performed using GATK. 580 
Lastly, SAMtools calmd was applied and indexes were created. 581 
 582 
Known indels for realignment were taken from the Mills Devine and 1000 Genomes Project 583 
Gold set and the 1000 Genomes Project phase low-coverage set, both part of the GATK 584 
resource bundle (version 2.2). Known variants for BQSR were taken from dbSNP 137, also part 585 
of the GATK resource bundle. Finally, single nucleotide variants (SNVs) and indels were called 586 
using the GATK HaplotypeCaller (version 3.2.2); this was run in multisample calling mode using 587 
the complete data set. GATK Variant Quality Score Recalibration (VQSR) was then computed on 588 
the whole data set and applied to the individual-sample variant calling format (VCF) files. 589 
DeNovoGear (version 0.54)39 was used to detect SNV, insertion and deletion de novo mutations 590 
(DNMs) from child and parental exome data (BAM files). 591 
 592 
Variant annotation 593 
Variants in the VCF were annotated with minor allele frequency (MAF) data from a variety of 594 
different sources. The MAF annotations used included data from four different populations of 595 
the 1000 Genomes Project40 (AMR, ASN, AFR and EUR), the UK10K cohort, the NHLBI GO Exome 596 
Sequencing Project (ESP), the Non-Finnish European (NFE) subset of the Exome Aggregation 597 
Consortium (ExAC) and an internal allele frequency generated using unaffected parents from 598 
the cohort.  599 
 600 
Variants in the VCF were annotated with Ensembl Variant Effect Predictor (VEP)41 based on 601 
Ensembl gene build 76. The transcript with the most severe consequence was selected and all 602 
associated VEP annotations were based on the predicted effect of the variant on that particular 603 
transcript; where multiple transcripts shared the same most severe consequence, the canonical 604 
or longest was selected. We included an additional consequence for variants at the last base of 605 
an exon before an intron, where the final base is a guanine, since these variants appear to be as 606 
damaging as a splice donor variant28. 607 
 608 
We categorized variants into three classes by VEP consequence:  609 
1. protein-truncating variants (PTV): splice donor, splice acceptor, stop gained, frameshift, 610 
initiator codon, and conserved exon terminus variant. 611 
2. missense variants: missense, stop lost, inframe deletion, inframe insertion, coding 612 
sequence, and protein altering variant. 613 
3. silent variants: synonymous. 614 
 615 
De novo mutation filtering 616 
We filtered candidate DNM calls to reduce the false positive rate but maximize sensitivity, 617 
based on prior results from experimental validation by capillary sequencing of candidate 618 
DNMs15. Candidate DNMs were excluded if not called by GATK in the child, or called in either 619 
parent, or if they had a maximum MAF greater than 0.01. Candidate DNMs were excluded 620 
when the forward and reverse coverage differed between reference and alternative alleles, 621 
defined as P < 10-3 from a Fisher’s exact test of coverage from orientation by allele summed 622 
across the child and parents.  623 
 624 
Candidate DNMs were also excluded if they met two of the three following three criteria: 1) an 625 
excess of parental alternative alleles within the cohort at the DNMs position, defined as P < 10-3 626 
under a one-sided binomial test given an expected error rate of 0.002 and the cumulative 627 
parental depth; 2) an excess of alternative alleles within the cohort in DNMs in a gene, defined 628 
as P < 10-3 under a one-sided binomial test given an expected error rate of 0.002 and the 629 
cumulative depth, or 3) both parents had one or more reads supporting the alternative allele.  630 
 631 
If, after filtering, more than one variant was observed in a given gene for a particular trio, only 632 
the variant with the highest predicted functional impact was kept (protein truncating > 633 
missense > silent).  634 
 635 
De novo mutation validation 636 
For candidate DNMs of interest, primers were designed to amplify 150-250 bp products 637 
centered around the site of interest. Default primer3 design settings were used with the 638 
following adjustments: GC clamp = 1, human mispriming library used. Site-specific primers were 639 
tailed with Illumina adapter sequences. PCR products were generated with JumpStart AccuTaq 640 
LA DNA polymerase (Sigma Aldrich), using 40 ng genomic DNA as template. Amplicons were 641 
tagged with Illumina PCR primers along with unique barcodes enabling multiplexing of 96 642 
samples. Barcodes were incorporated using Kapa HiFi mastermix (Kapa Biosystems). Samples 643 
were pooled and sequenced down one lane of the Illumina MiSeq, using 250 bp paired end 644 
reads. An in-house analysis pipeline extracted the read count per site and classified inheritance 645 
status per variant using a maximum likelihood approach (see Supplementary Note).  646 
 647 
Individuals with likely pathogenic variants 648 
We previously screened 1,133 individuals for variants that contribute to their disorder15,18. All 649 
candidate variants in the 1,133 individuals were reviewed by consultant clinical geneticists for 650 
relevance to the individuals’ phenotypes. Most diagnosable pathogenic variants occurred de 651 
novo in dominant genes, but a small proportion also occurred in recessive genes or under other 652 
inheritance modes. DNMs within dominant DD-associated genes were very likely to be 653 
classified as the pathogenic variant for the individuals’ disorder. Due to the time required to 654 
review individuals and their candidate variants, we did not conduct a similar review in the 655 
remainder of the 4,293 individuals. Instead we defined likely pathogenic variants as candidate 656 
DNMs found in autosomal and X-linked dominant DD-associated genes, or candidate DNMs 657 
found in hemizygous DD-associated genes in males. 1,136 individuals in the 4,293 cohort had 658 
variants either previously classified as pathogenic15,18, or had a likely pathogenic DNM. 659 
 660 
Gene-wise assessment of DNM significance 661 
Gene-specific germline mutation rates for different functional classes were computed15,23 for 662 
the longest transcript in the union of transcripts overlapping the observed DNMs in that gene. 663 
We evaluated the gene-specific enrichment of PTV and missense DNMs by computing its 664 
statistical significance under a null hypothesis of the expected number of DNMs given the gene-665 
specific mutation rate and the number of considered chromosomes23. 666 
 667 
We also assessed clustering of missense DNMs within genes15, as expected for DNMs operating 668 
by activating or dominant negative mechanisms. We did this by calculating simulated 669 
dispersions of the observed number of DNMs within the gene. The probability of simulating a 670 
DNM at a specific codon was weighted by the trinucleotide sequence-context15,23. This allowed 671 
us to estimate the probability of the observed degree of clustering given the null model of 672 
random mutations. 673 
 674 
Fisher’s method was used to combine the significance testing of missense + PTV DNM 675 
enrichment and missense DNM clustering. We defined a gene as significantly enriched for 676 
DNMs if the PTV enrichment P-value or the combined missense P-value less than 7 × 10-7, which 677 
represents a Bonferroni corrected P-value of 0.05 adjusted for 4 × 18500 tests (2 × consequence 678 
classes tested × protein coding genes). 679 
 680 
Composite face generation 681 
Families were given the option to have photographs of the affected individual(s) uploaded 682 
within DECIPHER34. Using images of individuals with DNMs in the same gene we generated de-683 
identified realistic average faces (composite faces). Faces were detected using a discriminately 684 
trained deformable part model detector42. The annotation algorithm identified a set of 36 685 
landmarks per detected face43 and was trained on a manually annotated dataset of 3100 686 
images24. The average face mesh was created by the Delaunay triangulation of the average 687 
constellation of facial landmarks for all patients with a shared genetic disorder.  688 
 689 
The averaging algorithm is sensitive to left-right facial asymmetries across multiple patients. For 690 
this purpose, we use a template constellation of landmarks based on the average constellations 691 
of 2000 healthy individuals24. For each patient, we align the constellation of landmarks to the 692 
template with respect to the points along the middle of the face and compute the Euclidean 693 
distances between each landmark and its corresponding pair on the template. The faces are 694 
mirrored such that the half of the face with the greater difference is always on the same side.  695 
 696 
The dataset used for this work may contain multiple photos for one patient. To avoid biasing 697 
the average face mesh towards these individuals, we computed an average face for each 698 
patient and use these personal averages to compute the final average face. Finally, to avoid any 699 
image in the composite dominating from variance in illumination between images, we 700 
normalised the intensities of pixel values within the face to an average value across all faces in 701 
each average. The composite faces were assessed visually to confirm successful ablation of any 702 
individually identifiable features. Visual assessment of the composite photograph by two 703 
experienced clinical geneticists, alongside the individual patient photos, was performed for all 704 
93 genome-wide significant DD-associated genes for which clinical photos were available for 705 
more than one patient, to remove potentially identifiable composite faces as well as quality 706 
control on the automated composite face generation process. Eighty-one composite faces were 707 
excluded leaving the twelve de-identified composite faces that are shown in Figure 2 and 708 
Extended Data Figure 3. Each of the twelve composite faces that passed de-identification and 709 
quality control was generated from photos of ten or more patients. 710 
 711 
Assessing power of incorporating phenotypic information 712 
We previously described a method to assess phenotypic similarity by HPO terms among groups 713 
of individuals sharing genetic defects in the same gene28. We examined whether incorporating 714 
this statistical test improved our ability to identify dominant genes at genome-wide 715 
significance. Per gene, we tested the phenotypic similarity of individuals with DNMs in the 716 
gene. We combined the phenotypic similarity P-value with the genotypic P-value per gene (the 717 
minimum P-value from the DDD-only and meta-analysis) using Fisher’s method. We examined 718 
the distribution of differences in P-value between tests without the phenotypic similarity P-719 
value and tests that incorporated the phenotypic similarity P-value. 720 
 721 
Many (854, 20%) of the DDD cohort experience seizures. We investigated whether testing 722 
within the subset of individuals with seizures improved our ability to find associations for 723 
seizure specific genes. A list of 102 seizure-associated genes was curated from three sources, a 724 
gene panel for Ohtahara syndrome, a currently used clinical gene panel for epilepsy and a panel 725 
derived from DD-associated genes18. The P-values from the seizure subset were compared to P-726 
values from the complete cohort. 727 
 728 
Assessing power of exome vs genome sequencing 729 
We compared the expected power of exome sequencing versus genome sequencing to identify 730 
disease genes. Within the DDD cohort, 55 dominant DD-associated genes achieve genome-wide 731 
significance when testing for enrichment of DNMs within genes. We did not incorporate 732 
missense DNM clustering due to the large computational requirements for assessing clustering 733 
in many replicates. 734 
 735 
We assumed a cost of 1,000 USD per individual for genome sequencing. We allowed the cost of 736 
exome sequencing to vary relative to genome sequencing, from 10-100%. We calculated the 737 
number of trios that could be sequenced under these scenarios. Estimates of the improved 738 
power of genome sequencing to detect DNMs in the coding sequence are around 1.05-fold29 739 
and we increased the number of trios by 1.0–1.2-fold to allow this. 740 
 741 
We sampled as many individuals from our cohort as the number of trios and counted which of 742 
the 55 DD-associated genes still achieved genome-wide significance for DNM enrichment. We 743 
ran 1000 simulations of each condition and obtained the mean number of genome-wide 744 
significant genes for each condition. 745 
 746 
Associations with presence of likely pathogenic de novo mutations 747 
We tested whether phenotypes were associated with the likelihood of having a likely 748 
pathogenic DNM. We analysed all collected phenotypes which could be coded in either a binary 749 
or quantitative format. Categorical phenotypes (e.g. sex coded as male or female) were tested 750 
by Fisher’s exact test while quantitative phenotypes (e.g. duration of gestation coded in weeks) 751 
were tested with logistic regression, using sex as a covariate. 752 
 753 
We investigated whether having autozygous regions affected the likelihood of having a 754 
diagnostic DNM. Autozygous regions were determined from genotypes in every individual, to 755 
obtain the total length per individual. We fitted a logistic regression for the total length of 756 
autozygous regions on whether individuals had a likely pathogenic DNM. To illustrate the 757 
relationship between length of autozygosity and the occurrence of a likely pathogenic DNM, we 758 
grouped the individuals by length and plotted the proportion of individuals in each group with a 759 
DNM against the median length of the group. 760 
 761 
The effects of parental age on the number of DNMs were assessed using 8,409 high confidence 762 
(posterior probability of DNM > 0.5) unphased coding and noncoding DNMs in 4,293 763 
individuals. A Poisson multiple regression was fit on the number of DNMs in each individual 764 
with both maternal and paternal age at the child’s birth as covariates. The model was fit with 765 
the identity link and allowed for overdispersion. This model used exome-based DNMs, and the 766 
analysis was scaled to the whole genome by multiplying the coefficients by a factor of 50, based 767 
on ~2% of the genome being well covered in our data (exons + introns). 768 
 769 
Excess of de novo mutations by consequence 770 
We identified the threshold for posterior probability of DNM at which the number of observed 771 
candidate synonymous DNMs equalled the number of expected synonymous DNMs. Candidate 772 
DNMs with scores below this threshold were excluded. We also examined the likely sensitivity 773 
and specificity of this threshold based on validation results for DNMs within a previous 774 
publication15 in which comprehensive experimental validation was performed on 1,133 trios 775 
that comprise a subset of the families analysed here.  776 
 777 
The numbers of expected DNMs per gene were calculated per consequence from expected 778 
mutation rates per gene and the 2,407 male and 1,886 females in the cohort. We calculated the 779 
excess of DNMs for missense and PTVs as the ratio of numbers of observed DNMs versus 780 
expected DNMs, as well as the difference of observed DNMs minus expected DNMs. 781 
 782 
Ascertainment bias within dominant neurodevelopmental genes 783 
We identified 150 autosomal dominant haploinsufficient genes that affect neurodevelopment 784 
within our curated developmental disorder gene set. Genes affecting neurodevelopment were 785 
identified where the affected organs included the brain, or where HPO phenotypes linked to 786 
defects in the gene included either an abnormality of brain morphology (HP:0012443) or 787 
cognitive impairment (HP:0100543) term.  788 
 789 
The 150 genes were classified for ease of clinical recognition of the syndrome from gene 790 
defects by two consultant clinical geneticists. Genes were rated from 1 (least recognisable) to 5 791 
(most recognisable). Categories 1 and 2 contained 5 and 22 genes respectively, and so were 792 
combined in later analyses. The remaining categories had more than 33 genes per category. 793 
The ratio of observed loss-of-function DNMs to expected loss-of-function DNMs was calculated 794 
for each recognisability category, along with 95% confidence intervals from a Poisson 795 
distribution given observed counts.  796 
 797 
We estimated the likelihood of obtaining the observed number of PTV DNMs under two 798 
models. Our first model assumed no haploinsufficiency, and mutation counts were expected to 799 
follow baseline mutation rates. Our second model assumed fully penetrant haploinsufficiency, 800 
and scaled the baseline PTV mutation expectations by the observed PTV enrichment in our 801 
known haploinsufficient neurodevelopmental genes, stratified by clinical recognisability into 802 
low (containing genes with our “low”, “mild” and “moderate” labels) and high categories. We 803 
calculated the likelihoods of both models per gene as the Poisson probability of obtaining the 804 
observed number of PTVs, given the expected mutation rates. We computed the Akaike’s 805 
Information Criterion for each model and ranked them by the difference between model 1 and 806 
model 2 (ΔAIC). 807 
 808 
Proportion of de novo mutations with loss-of-function mechanism 809 
The observed excess of missense/inframe indel DNMs is composed of a mixture of DNMs with 810 
loss-of-function mechanisms and DNMs with altered-function mechanisms. We found that the 811 
excess of PTV DNMs within dominant haploinsufficient DD-associated genes had a greater skew 812 
towards genes with high intolerance for loss-of-function variants than the excess of missense 813 
DNMs in dominant non-haploinsufficient genes. We binned genes by the probability of being 814 
loss-of-function intolerant30 constraint decile and calculated the observed excess of missense 815 
DNMs in each bin. We modelled this binned distribution as a two-component mixture with the 816 
components representing DNMs with a loss-of-function or function-altering mechanism. We 817 
identified the optimal mixing proportion for the loss-of-function and altered-function DNMs 818 
from the lowest goodness-of-fit (from a spline fitted to the sum-of-squares of the differences 819 
per decile) to missense/inframe indels in all genes across a range of mixtures. 820 
 821 
The excess of DNMs with a loss-of-function mechanism was calculated as the excess of DNMs 822 
with a VEP loss-of-function consequence, plus the proportion of the excess of missense DNMs 823 
at the optimal mixing proportion. 824 
 825 
We independently estimated the proportions of loss-of-function and altered-function. We 826 
counted PTV and missense/inframe indel DNMs within dominant haploinsufficient genes to 827 
estimate the proportion of excess DNMs with a loss-of-function mechanism, but which were 828 
classified as missense/inframe indel. We estimated the proportion of excess DNMs with a loss-829 
of-function mechanism as the PTV excess plus the PTV excess multiplied by the proportion of 830 
loss-of-function classified as missense. 831 
 832 
Prevalence of developmental disorders from dominant de novo mutations 833 
We estimated the birth prevalence of monoallelic developmental disorders by using the 834 
germline mutation model. We calculated the expected cumulative germline mutation rate of 835 
truncating DNMs in 238 haploinsufficient DD-associated genes. We scaled this upwards based 836 
on the composition of excess DNMs in the DDD cohort using the ratio of excess DNMs (n=1816) 837 
to DNMs within dominant haploinsufficient DD-associated genes (n=412). Around 10% of DDs 838 
are caused by de novo CNVs44,45, which are underrepresented in our cohort as a result of prior 839 
genetic testing. If included, the excess DNM in our cohort would increase by 21%, therefore we 840 
scaled the prevalence estimate upwards by this factor.  841 
 842 
Mothers aged 29.9 and fathers aged 29.5 have children with 77 DNMs per genome on 843 
average21. We calculated the mean number of DNMs expected under different combinations of 844 
parental ages, given our estimates of the extra DNMs per year from older mothers and fathers. 845 
We scaled the prevalence to different combinations of parental ages using the ratio of expected 846 
mutations at a given age combination to the number expected at the mean cohort parental 847 
ages.  848 
 849 
To estimate the annual number of live births with developmental disorders caused by DNMs, 850 
we obtained country population sizes, birth rates, age at first birth46, and calculated global birth 851 
rate (18.58 live births/1000 individuals) and age at first birth (22.62 years), weighted by 852 
population size. We calculated the mean age when giving birth (26.57 years) given a total 853 
fertility rate of 2.45 children per mother47, and a mean interpregnancy interval of 29 months48. 854 
We calculated the number of live births given our estimate of DD prevalence caused by DNMs 855 
at this age (0.00288), the global population size (7.4 billion individuals) and the global birth rate.  856 
 857 
Code availability 858 
Source code for filtering candidate DNMs, testing DNM enrichment, DNM clustering and 859 
phenotypic similarity can be found here: https://github.com/jeremymcrae/denovoFilter, 860 
https://github.com/jeremymcrae/mupit, https://github.com/jeremymcrae/denovonear, 861 
https://github.com/jeremymcrae/hpo_similarity 862 
  863 
Extended data figure captions 864 
 865 
 866 
Extended Data Figure 1: Proportion of individuals with a de novo mutation (DNM) likely to be 867 
pathogenic. These only included individuals with protein altering or protein truncating DNMs in 868 
dominant or X-linked dominant developmental disorder (DD) associated genes, or males with DNMs in 869 
hemizygous DD-associated genes. The proportions given are for those individuals with any DNMs rather 870 
than the total number of individuals in each subset. Cohorts included in the DNM meta-analyses are 871 
shaded blue. 872 
  873 
 874 
Extended Data Figure 2: Phenotypic summary of genes without previous compelling evidence. 875 
Phenotypes are grouped by type. The first group indicates counts of individuals with DNMs per gene by 876 
sex (m: male, f: female), and by functional consequence (nsv: nonsynonymous variant, PTV: protein-877 
truncating variant). The second group indicates mean values for growth parameters: birthweight (bw), 878 
height (ht), weight (wt), occipitofrontal circumference (OFC). Values are given as standard deviations 879 
from the healthy population mean derived from ALSPAC data. The third group indicates the mean age 880 
for achieving developmental milestones: age of first social smile, age of first sitting unassisted, age of 881 
first walking unassisted and age of first speaking. Values are given in months. The final group 882 
summarises Human Phenotype Ontology (HPO)-coded phenotypes per gene, as counts of HPO-terms 883 
within different clinical categories. 884 
  885 
 886 
Extended Data Figure 3: Phenotypic summary of individuals with de novo mutations in genes achieving 887 
genomewide significance. Phenotypes are grouped by type. The first group indicates counts of 888 
individuals with DNMs per gene by sex (m: male, f: female), and by functional consequence (nsv: 889 
nonsynonymous variant, PTV: protein-truncating variant). The second group indicates mean values for 890 
growth parameters: birthweight (bw), height (ht), weight (wt), occipitofrontal circumference (OFC). 891 
Values are given as standard deviations from the healthy population mean derived from ALSPAC data. 892 
The third group indicates the mean age for achieving developmental milestones: age of first social smile, 893 
age of first sitting unassisted, age of first walking unassisted and age of first speaking. Values are given in 894 
months. The final group summarises Human Phenotype Ontology (HPO)-coded phenotypes per gene, as 895 
counts of HPO-terms within different clinical categories.  896 
 897 
Extended Data Figure 4: Dispersion of de novo mutations and domains for each novel gene. a, CDK13, b, 898 
CHD4, c, CNOT3, d, CSNK2A1, e, GNAI1, f, KCNQ3, g, MSL3, h, PPM1D, I, PUF60, j, QRICH1, k, SET, l, 899 
SUV420H1, m, TCF20 and n, ZBTB18. 900 
  901 
 902 
Extended Data Figure 5: Effect of clustering by phenotype on the ability to identify genomewide 903 
significant genes. a, Comparison of P-values derived from genotypic information alone versus P-values 904 
that incorporate genotypic information and phenotypic similarity. b, Comparison of P-values from tests 905 
in the complete DDD cohort versus tests in the subset with seizures. Genes that were previously linked 906 
to seizures are shaded blue. c, Proportion of cohort with a de novo mutation (DNM) in a seizure-907 
associated gene, stratified by whether seizure-affected status. Bars indicate 95% CI. d, Comparison of 908 
power to identify genomewide significant genes in probands with seizures, versus the unstratified 909 
cohort, at matched sample sizes. 910 
  911 
 912 
Extended Data Figure 6: Power of genome versus exome sequencing to discover dominant genes 913 
associated with developmental disorders. a, the number of genes exceeding genome-wide significance 914 
was estimated at three different fixed budgets (1 million (M) USD, 2M and 3M) and a range of relative 915 
sensitivities for genomes versus exomes to detect de novo mutations. The number of genes identifiable 916 
by exome sequencing are shaded blue, whereas the number of genes identifiable by genome 917 
sequencing are shaded green. The regions where exome sequencing costs 30-40% of genome 918 
sequencing are shaded with a grey background, which corresponds to the price differential in 2016. b, 919 
simulated estimates of power to detect loss-of-function genes in the genome at different cohort sizes, 920 
given fixed budgets. 921 
  922 
 923 
Extended Data Figure 7: Gene-wise significance of neurodevelopmental genes versus the expected 924 
number of mutations per gene. Points are shaded by clinical recognisability classification. Genes have 925 
been separated into two plots, one plot with genes for cryptic disorders with low, mild or moderate 926 
clinical recognisability, and one plot with genes for distinctive disorders with high clinical recognisability. 927 
 928 
  929 
 930 
Extended Data Figure 8: Stringency of de novo mutation (DNM) filtering. a, Sensitivity and specificity of 931 
DNM validations within sets filtered on varying thresholds of DNM quality (posterior probability of 932 
DNM). The analysed DNMs were restricted to sites identified within the earlier 1133 trios15, where all 933 
candidate DNMs underwent validation experiments. The labelled value is the quality threshold at which 934 
the number of candidate synonymous DNMs equals the number of expected synonymous mutations 935 
under a null germline mutation rate. b, Excess of missense and loss-of-function DNMs at varying DNM 936 
quality thresholds. The DNM excess is adjusted for the sensitivity and specificity at each threshold. 937 
  938 
 939 
Extended Data Figure 9: Enrichment of de novo mutations by consequence type, across RVIS functional 940 
constraint quantiles. A comparison of enrichment for RVIS values generated from ESP6500 data versus 941 
ExAC data is provided. 942 
 943 
